Lead Product(s) : Nicardipine Hydrochloride
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Nicardipine Hydrochloride Capsules is a calcium channel blocker indicated for the short-term treatment of hypertension when oral therapy is not feasible.
Product Name : Nicardipine Hydrochloride-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 25, 2023
Lead Product(s) : Nicardipine Hydrochloride
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nicardipine Hydrochloride
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Nicardipine Hydrochloride Capsules, 20 mg and 30 mg, is the generic version of Cardene®1 Capsules, 20 mg and 30 mg, of Chiesi USA, Inc. Nicardipine Hydrochloride capsules, will be distributed in the U.S. by Glenmark Pharmaceuticals Inc., USA.
Product Name : Nicardipine Hydrochloride-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 19, 2022
Lead Product(s) : Nicardipine Hydrochloride
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nicardipine Hydrochloride,Emu oil
Therapeutic Area : Dermatology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : H-100 (nicardipine), a novel, patented, non-invasive topical treatment being developed for Peyronie’s disease, is being developed as a topical gel using nanotechnology to potentially enhance permeation of the medication.
Product Name : H100
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 05, 2022
Lead Product(s) : Nicardipine Hydrochloride,Emu oil
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nicardipine Hydrochloride,Emu oil
Therapeutic Area : Dermatology
Study Phase : Phase I
Sponsor : Hybrid Medical
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : H-100 may be able to provide the first-ever non-invasive treatment to a confounding and often painful condition for which there have been few viable solutions. As a topical, H-100 has the potential to be approved as the first non-invasive treatment for t...
Product Name : H100
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 11, 2021
Lead Product(s) : Nicardipine Hydrochloride,Emu oil
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Sponsor : Hybrid Medical
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
